Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,202.00    -43.00 (-1.92%)
Bid:
2,204.00
Ask:
2,206.00
Spread: 2.00 (0.091%)
Market Cap: £22.24b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Commencement of Share Buyback Programme

14 May 2026 07:02

RNS Number : 2344E
3i Group PLC
14 May 2026
 

 

 

This announcement contains inside information for the purposes of Article 7 of the UK version of the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement, this information is considered to be in the public domain.

 

3i Group plc to commence share buyback programme of up to £750 million

 

3i Group plc ("3i" or the "Company") announces that it will commence a share buyback programme of its ordinary shares of 73 19/22p each ("Shares") for up to a maximum aggregate consideration of £750 million (the "Programme").

The Programme will commence on 14 May 2026 and complete by no later than 31 December 2026. 3i has entered into an arrangement with Barclays Bank PLC, acting through its investment bank (the "Broker") to undertake the Programme by making market purchases, as riskless principal, of the Shares on the London Stock Exchange or another recognised investment exchange (the "Agreement").

The Broker will make trading decisions under the Programme independently of 3i, subject to certain parameters agreed between the Broker and 3i prior to the commencement of the Programme and to 3i's right to terminate the Agreement.

Shares acquired by the Broker will subsequently be sold on to 3i and will be cancelled. The purpose of the Programme is therefore to reduce 3i's share capital. 

Prior to the Company's 2026 Annual General Meeting (the "2026 AGM"), the maximum number of Shares that can be purchased under the Programme is 97,000,000 Shares as authorised by shareholders at the Company's 2025 Annual General Meeting on 26 June 2025 (the "Existing Authority"). The Existing Authority will expire at the earlier of 25 September 2026 or the 2026 AGM, where the Company expects to seek renewal of the Existing Authority (the "Renewed Authority"). The continuation of the Programme following the 2026 AGM is subject to approval of the Renewed Authority and purchases of Shares pursuant to the Programme remaining within the Renewed Authority (if applicable).

Any purchase of Shares under the Programme will be executed in accordance with the Existing Authority and any subsequent authority, the Market Abuse Regulation 596/2014 and the Commission Delegated Regulation (EU) 2016/1052 (both as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), and Chapter 9 of the Financial Conduct Authority's UK Listing Rules.

Repurchases of Shares under the Programme will be announced by no later than the end of the seventh daily market session following the calendar day on which the relevant repurchase occurred.

 

 

For further information, contact:

 

3i Group plc

 

Silvia Santoro

Investor enquiries

 

Kathryn van der Kroft

Media enquiries

 

 

 

Tel: +44 20 7975 3258

Email: silvia.santoro@3i.com

 

Tel: +44 20 7975 3021

Email: kathryn.vanderkroft@3i.com

 

Legal Entity Identifier: 35GDVHRBMFE7NWATNM84

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUOABRNWUVAAR
Date   Source Headline
15th Jun 20267:00 amRNSTransaction in Own Shares
8th Jun 202611:21 amRNSDirector/PDMR Shareholding
8th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20264:24 pmRNSDirector/PDMR Shareholding
2nd Jun 20263:37 pmRNSDirector/PDMR Shareholding - Amendment
1st Jun 20264:28 pmRNSDirector/PDMR Shareholding
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:42 pmRNSTotal Voting Rights
29th May 20265:38 pmRNSAdmission to Trading
27th May 202610:42 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 202612:29 pmRNSDirector/PDMR Shareholding
21st May 20267:40 amRNSDoc re. 2026 Annual Report and Accounts
19th May 20262:28 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:24 amRNSDirector/PDMR Shareholding
14th May 202610:41 amRNSHolding(s) in Company
14th May 20267:02 amRNSCommencement of Share Buyback Programme
14th May 20267:00 amRNSResults for the year to 31 March 2026
1st May 202612:00 pmRNSDirector/PDMR Shareholding
30th Apr 20263:34 pmRNSTotal Voting Rights
30th Apr 20263:31 pmRNSAdmission to Trading
7th Apr 202612:33 pmRNSHolding(s) in Company
1st Apr 20269:53 amRNSPortfolio Update
1st Apr 20269:36 amRNSDirector/PDMR Shareholding
31st Mar 20262:30 pmRNSTotal Voting Rights
31st Mar 20262:29 pmRNSAdmission to Trading
31st Mar 202611:37 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:07 pmRNSAdmission to Trading
26th Mar 20267:00 amRNSAction Capital Markets Seminar & portfolio update
23rd Mar 202612:11 pmRNSHolding(s) in Company
2nd Mar 202612:18 pmRNSDirector/PDMR Shareholding
27th Feb 20264:00 pmRNSTotal Voting Rights
3rd Feb 202610:20 amRNSHolding(s) in Company
3rd Feb 202610:17 amRNSDirector Declaration
30th Jan 20262:24 pmRNSDirector/PDMR Shareholding
30th Jan 20261:47 pmRNSTotal Voting Rights
29th Jan 202612:19 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSFY2026 Q3 performance update
7th Jan 20262:06 pmRNSDirector/PDMR Shareholding
6th Jan 20261:53 pmRNSTotal Voting Rights
2nd Jan 202611:06 amRNSPortfolio Update
9th Dec 20251:11 pmRNSBlock listing Interim Review
4th Dec 20252:12 pmRNSDirector/PDMR Shareholding
1st Dec 20251:25 pmRNSDirector/PDMR Shareholding
28th Nov 20254:24 pmRNSTotal Voting Rights
20th Nov 20259:59 amRNSDirector/PDMR Shareholding
18th Nov 20252:23 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.